Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
1.970
+0.040 (2.07%)
At close: Aug 13, 2025, 4:00 PM
1.950
-0.020 (-1.02%)
Pre-market: Aug 14, 2025, 9:07 AM EDT
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$277,497
Profits / Employee
-$956,848
Market Cap
447.94M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GOSS News
- 6 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - Business Wire
- 3 months ago - Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Business Wire
- 3 months ago - Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Business Wire
- 3 months ago - Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - Business Wire
- 5 months ago - Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - Business Wire